Study highlights the ability of the Vaxzevria vaccine in inducing robust mucosal antibody responses, especially in COVID-19-recovered individuals, showcasing a notable defense against various SARS-CoV-2 variants. However, it emphasizes the need for booster doses to enhance anti-SARS-CoV-2 mucosal immunity, especially in infection-naïve individuals, to broaden protection against emerging viral variants.
Early data are promising for autoimmune disease drug from Roivant Sciences’s Immunovant
Results released Tuesday from an early study of an autoimmune disease drug from Roivant Sciences’s Immunovant showed the treatment could reduce the levels of a